MedTrace Logo

A Study of SHR-1501 in Patients With Advanced Tumors

NCT04025957 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-09-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in patients with advanced malignancies .

Conditions

  • Advanced Malignancies

Interventions

DRUG

SHR-1501

Administered subcutaneously

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jing Huang, MD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-30
Primary Completion
2022-07-31
Completion
2022-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04025957 on ClinicalTrials.gov